Biosimilars in the Era of Artificial Intelligence—International Regulations and the Use in Oncological Treatments
This research is based on three fundamental aspects of successful biosimilar development
in the challenging biopharmaceutical market. First, biosimilar regulations in eight selected …
in the challenging biopharmaceutical market. First, biosimilar regulations in eight selected …
Co-creation of the Global Patient Experience Data Navigator: a multi-stakeholder initiative to ensure the patient voice is represented in health decision-making
T Willgoss, OA Escontrias, C Scrafton… - Research Involvement …, 2023 - Springer
Background Putting patients' needs and priorities at the forefront of healthcare initiatives and
medical product development is critical to achieve outcomes that matter most to patients …
medical product development is critical to achieve outcomes that matter most to patients …
Patient preferences for mitral valve regurgitation treatment: a discrete choice experiment
Introduction This study aimed to quantify patients' preferences for benefits and risks
associated with treating degenerative mitral regurgitation (DMR) via open heart surgical …
associated with treating degenerative mitral regurgitation (DMR) via open heart surgical …
Patient feasibility as a novel approach for integrating IRT and LCA statistical models into patient-centric qualitative data—a pilot study
M Klüglich, B Santy, M Tanev, K Hristov… - Frontiers in Digital …, 2024 - frontiersin.org
Introduction Clinical research increasingly recognizes the role and value of patient-centric
data incorporation in trial design, aiming for more relevant, feasible, and engaging studies …
data incorporation in trial design, aiming for more relevant, feasible, and engaging studies …
Mitigating Evidence Gaps: A Survey Template to Inform Patient-Centered Value Assessment
KR Majercak - 2024 - search.proquest.com
Background: Necessary and informative patient-experience data (PED) needed for
value/health technology assessments (V/HTA) are rarely available as they are not routinely …
value/health technology assessments (V/HTA) are rarely available as they are not routinely …